(4-benzyl-phenyl)-(2-chloro-ethyl)-ether | 297174-87-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-benzyl-phenyl)-(2-chloro-ethyl)-ether
• 英文别名: (4-Benzyl-phenyl)-(2-chlor-aethyl)-aether；1-(2-chloroethoxy)-4-(benzyl)benzene；1-(2-Chloroethoxy)4-(benzyl)benzene；1-benzyl-4-(2-chloroethoxy)benzene
• CAS: 297174-87-9
• 化学式: C₁₅H₁₅ClO
• 分子量: 246.737
• InChiKey: YEGUFOJANZTJPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (4-benzyl-phenyl)-(2-chloro-ethyl)-ether 在 potassium carbonate 、 间氯过氧苯甲酸 作用下， 以 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-[2-(4-Benzyl-phenoxy)-ethyl]-3H-imidazo[4,5-c]pyridine 5-oxide
  参考文献：
  名称：

  Synthesis of Imidazopyridines and Purines as Potent Inhibitors of Leukotriene A4 Hydrolase

  摘要：

  The synthesis and biological evaluation of a series of heterocyclic analogues of the previously reported LTA(4) hydrolase inhibitor 1b are described. Imidazopyridine and purine analogues are specifically highlighted with several demonstrating excellent potency in our in vitro assays, as well as good oral activity in a mouse ex vivo assay. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00039-8
• 作为产物：
  描述：

  4-羟基二苯甲烷 、 1-溴-2-氯乙烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.5h， 生成 (4-benzyl-phenyl)-(2-chloro-ethyl)-ether
  参考文献：
  名称：

  强大的白三烯A（4）水解酶抑制剂的合成。鉴定3- [甲基[3- [4-（苯基甲基）苯氧基]丙基]氨基]丙酸。

  摘要：

  白三烯B（4）（LTB（4））是一种强效的促炎介质，参与多种疾病的发病机理，包括炎症性肠病，牛皮癣，类风湿性关节炎和哮喘。LTA（4）水解酶代表了在这些疾病状态下进行药物干预的诱人靶标，因为该酶的作用是LTB（4）生产中的限速步骤。我们先前的工作重点是探索与筛选热门SC-22716（1，1- [2-（4-苯基苯氧基）乙基]吡咯烷）有关的一系列类似物，并确定了有效的口服活性抑制剂，例如2 。围绕该结构类别进行的其他结构-活性关系研究导致鉴定出一系列α-，β-，和γ-氨基酸类似物，它们是LTA（4）水解酶的有效抑制剂，在小鼠离体全血LTB（4）生产测定中显示出良好的口服活性。描述了导致鉴定临床候选SC-57461A（8d，3- [甲基[3- [4-（苯基甲基）苯氧基]丙基]氨基]丙酸的努力）。

  DOI：

  10.1021/jm0200916

文献信息

• Diamine derivatives as inhibitors of leukotriene A4 hydrolase
  申请人：Arnaiz Damian

  公开号：US20070155726A1

  公开（公告）日：2007-07-05

  This invention is directed to compounds of formula (I): where r, q, R, R 2 , R 3 , R 4 , R 5a , R 5b , R 5c , R 6a , R 6b , R 6c , R 7 , R 8 , and R 9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A 4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

  这项发明涉及式(I)的化合物： 其中r、q、R、R2、R3、R4、R5a、R5b、R5c、R6a、R6b、R6c、R7、R8和R9如本文所述，可以是单一立体异构体或立体异构体混合物，或其药学上可接受的盐、溶剂合物、包合物、多型体、铵离子、N-氧化物或其前药；这些化合物是白三烯A4水解酶抑制剂，因此在治疗炎症性疾病中有用。还公开了包括该发明化合物的药物组合物以及制备该发明化合物的方法。
• LTA4 Hydrolase inhibitors
  申请人：G.D. SEARLE & CO.

  公开号：EP1221441A2

  公开（公告）日：2002-07-10

  The present invention provides compounds of the formula Ar1-Q-Ar2-Y-R-Z and pharmaceutically acceptable salts thereof wherein Ar1 and Ar2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB4 production, such as proriasis, ulcerative colitis, IBD and asthma.

  本发明提供了具有公式Ar1-Q-Ar2-Y-R-Z的化合物及其药用可接受的盐，其中Ar1和Ar2是可选地取代的芳基部分，Z是可选地取代的含氮部分，可以是环状、环状或双环状的胺，或可选地取代的单环或双环的含氮杂芳基部分；Q是能够连接两个芳基团的连接基团；R是烷基亚基；Y是能够连接芳基团和烷基亚基的连接基团，并且其中Z通过氮原子与R键合。本发明的化合物和药物组合物在治疗由LTB4产生介导的炎症性疾病中是有用的，例如银屑病、溃疡性结肠炎、炎症性肠病和哮喘。
• DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE
  申请人：Celtaxsys, Inc.

  公开号：US20150080382A1

  公开（公告）日：2015-03-19

  This invention is directed to compounds of formula (I): where r, q, R, R 2 , R 3 , R 4 , R 5a , R 5b , R 5c , R 6a , R 6b , R 6c , R 7 , R 8 , and R 9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A 4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

  该发明涉及式（I）的化合物：其中r、q、R、R2、R3、R4、R5a、R5b、R5c、R6a、R6b、R6c、R7、R8和R9如本文所述，作为单一立体异构体或立体异构体混合物，或其药学上可接受的盐、溶剂化合物、包合物、多晶体、铵离子、N-氧化物或其前药；这些化合物是白三烯A4水解酶抑制剂，因此可用于治疗炎症性疾病。本发明还公开了包含该化合物的制药组合物以及制备该化合物的方法。
• Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase
  申请人：Arnaiz Damian

  公开号：US20100210630A1

  公开（公告）日：2010-08-19

  This invention is directed to compounds of formula (I): where r, q, R, R 2 , R 3 , R 4 , R 5a , R 5b , R 5c , R 6a , R 6b , R 6c , R 7 , R 8 , and R 9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A 4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

  本发明涉及化合物的公式(I)：其中r、q、R、R2、R3、R4、R5a、R5b、R5c、R6a、R6b、R6c、R7、R8和R9如本文所述，可以作为单一立体异构体或立体异构体混合物，或其药学上可接受的盐、溶剂合物、包合物、多晶体、铵离子、N-氧化物或前药；这些化合物是白三烯A4水解酶抑制剂，因此在治疗炎症性疾病方面有用。本发明还公开了包含该化合物的制药组合物以及制备该化合物的方法。
• o-Benzylphenyl Derivatives. IV.¹ β-Chloroethylamines
  作者：William B. Wheatley、William E. Fitzgibbon、Lee C. Cheney、S. B. Binkley

  DOI：10.1021/ja01160a065

  日期：1950.4